Cargando…

Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

BACKGROUND: Pathological response to neoadjuvant treatment for patients with high-grade serous ovarian carcinoma (HGSOC) is assessed using the chemotherapy response score (CRS) for omental tumor deposits. The main limitation of CRS is that it requires surgical sampling after initial neoadjuvant chem...

Descripción completa

Detalles Bibliográficos
Autores principales: Rundo, Leonardo, Beer, Lucian, Escudero Sanchez, Lorena, Crispin-Ortuzar, Mireia, Reinius, Marika, McCague, Cathal, Sahin, Hilal, Bura, Vlad, Pintican, Roxana, Zerunian, Marta, Ursprung, Stephan, Allajbeu, Iris, Addley, Helen, Martin-Gonzalez, Paula, Buddenkotte, Thomas, Singh, Naveena, Sahdev, Anju, Funingana, Ionut-Gabriel, Jimenez-Linan, Mercedes, Markowetz, Florian, Brenton, James D., Sala, Evis, Woitek, Ramona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243357/
https://www.ncbi.nlm.nih.gov/pubmed/35785153
http://dx.doi.org/10.3389/fonc.2022.868265
_version_ 1784738288803774464
author Rundo, Leonardo
Beer, Lucian
Escudero Sanchez, Lorena
Crispin-Ortuzar, Mireia
Reinius, Marika
McCague, Cathal
Sahin, Hilal
Bura, Vlad
Pintican, Roxana
Zerunian, Marta
Ursprung, Stephan
Allajbeu, Iris
Addley, Helen
Martin-Gonzalez, Paula
Buddenkotte, Thomas
Singh, Naveena
Sahdev, Anju
Funingana, Ionut-Gabriel
Jimenez-Linan, Mercedes
Markowetz, Florian
Brenton, James D.
Sala, Evis
Woitek, Ramona
author_facet Rundo, Leonardo
Beer, Lucian
Escudero Sanchez, Lorena
Crispin-Ortuzar, Mireia
Reinius, Marika
McCague, Cathal
Sahin, Hilal
Bura, Vlad
Pintican, Roxana
Zerunian, Marta
Ursprung, Stephan
Allajbeu, Iris
Addley, Helen
Martin-Gonzalez, Paula
Buddenkotte, Thomas
Singh, Naveena
Sahdev, Anju
Funingana, Ionut-Gabriel
Jimenez-Linan, Mercedes
Markowetz, Florian
Brenton, James D.
Sala, Evis
Woitek, Ramona
author_sort Rundo, Leonardo
collection PubMed
description BACKGROUND: Pathological response to neoadjuvant treatment for patients with high-grade serous ovarian carcinoma (HGSOC) is assessed using the chemotherapy response score (CRS) for omental tumor deposits. The main limitation of CRS is that it requires surgical sampling after initial neoadjuvant chemotherapy (NACT) treatment. Earlier and non-invasive response predictors could improve patient stratification. We developed computed tomography (CT) radiomic measures to predict neoadjuvant response before NACT using CRS as a gold standard. METHODS: Omental CT-based radiomics models, yielding a simplified fully interpretable radiomic signature, were developed using Elastic Net logistic regression and compared to predictions based on omental tumor volume alone. Models were developed on a single institution cohort of neoadjuvant-treated HGSOC (n = 61; 41% complete response to NCT) and tested on an external test cohort (n = 48; 21% complete response). RESULTS: The performance of the comprehensive radiomics models and the fully interpretable radiomics model was significantly higher than volume-based predictions of response in both the discovery and external test sets when assessed using G-mean (geometric mean of sensitivity and specificity) and NPV, indicating high generalizability and reliability in identifying non-responders when using radiomics. The performance of a fully interpretable model was similar to that of comprehensive radiomics models. CONCLUSIONS: CT-based radiomics allows for predicting response to NACT in a timely manner and without the need for abdominal surgery. Adding pre-NACT radiomics to volumetry improved model performance for predictions of response to NACT in HGSOC and was robust to external testing. A radiomic signature based on five robust predictive features provides improved clinical interpretability and may thus facilitate clinical acceptance and application.
format Online
Article
Text
id pubmed-9243357
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92433572022-07-01 Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma Rundo, Leonardo Beer, Lucian Escudero Sanchez, Lorena Crispin-Ortuzar, Mireia Reinius, Marika McCague, Cathal Sahin, Hilal Bura, Vlad Pintican, Roxana Zerunian, Marta Ursprung, Stephan Allajbeu, Iris Addley, Helen Martin-Gonzalez, Paula Buddenkotte, Thomas Singh, Naveena Sahdev, Anju Funingana, Ionut-Gabriel Jimenez-Linan, Mercedes Markowetz, Florian Brenton, James D. Sala, Evis Woitek, Ramona Front Oncol Oncology BACKGROUND: Pathological response to neoadjuvant treatment for patients with high-grade serous ovarian carcinoma (HGSOC) is assessed using the chemotherapy response score (CRS) for omental tumor deposits. The main limitation of CRS is that it requires surgical sampling after initial neoadjuvant chemotherapy (NACT) treatment. Earlier and non-invasive response predictors could improve patient stratification. We developed computed tomography (CT) radiomic measures to predict neoadjuvant response before NACT using CRS as a gold standard. METHODS: Omental CT-based radiomics models, yielding a simplified fully interpretable radiomic signature, were developed using Elastic Net logistic regression and compared to predictions based on omental tumor volume alone. Models were developed on a single institution cohort of neoadjuvant-treated HGSOC (n = 61; 41% complete response to NCT) and tested on an external test cohort (n = 48; 21% complete response). RESULTS: The performance of the comprehensive radiomics models and the fully interpretable radiomics model was significantly higher than volume-based predictions of response in both the discovery and external test sets when assessed using G-mean (geometric mean of sensitivity and specificity) and NPV, indicating high generalizability and reliability in identifying non-responders when using radiomics. The performance of a fully interpretable model was similar to that of comprehensive radiomics models. CONCLUSIONS: CT-based radiomics allows for predicting response to NACT in a timely manner and without the need for abdominal surgery. Adding pre-NACT radiomics to volumetry improved model performance for predictions of response to NACT in HGSOC and was robust to external testing. A radiomic signature based on five robust predictive features provides improved clinical interpretability and may thus facilitate clinical acceptance and application. Frontiers Media S.A. 2022-06-16 /pmc/articles/PMC9243357/ /pubmed/35785153 http://dx.doi.org/10.3389/fonc.2022.868265 Text en Copyright © 2022 Rundo, Beer, Escudero Sanchez, Crispin-Ortuzar, Reinius, McCague, Sahin, Bura, Pintican, Zerunian, Ursprung, Allajbeu, Addley, Martin-Gonzalez, Buddenkotte, Singh, Sahdev, Funingana, Jimenez-Linan, Markowetz, Brenton, Sala and Woitek https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Rundo, Leonardo
Beer, Lucian
Escudero Sanchez, Lorena
Crispin-Ortuzar, Mireia
Reinius, Marika
McCague, Cathal
Sahin, Hilal
Bura, Vlad
Pintican, Roxana
Zerunian, Marta
Ursprung, Stephan
Allajbeu, Iris
Addley, Helen
Martin-Gonzalez, Paula
Buddenkotte, Thomas
Singh, Naveena
Sahdev, Anju
Funingana, Ionut-Gabriel
Jimenez-Linan, Mercedes
Markowetz, Florian
Brenton, James D.
Sala, Evis
Woitek, Ramona
Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
title Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
title_full Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
title_fullStr Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
title_full_unstemmed Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
title_short Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
title_sort clinically interpretable radiomics-based prediction of histopathologic response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243357/
https://www.ncbi.nlm.nih.gov/pubmed/35785153
http://dx.doi.org/10.3389/fonc.2022.868265
work_keys_str_mv AT rundoleonardo clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT beerlucian clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT escuderosanchezlorena clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT crispinortuzarmireia clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT reiniusmarika clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT mccaguecathal clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT sahinhilal clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT buravlad clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT pinticanroxana clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT zerunianmarta clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT ursprungstephan clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT allajbeuiris clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT addleyhelen clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT martingonzalezpaula clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT buddenkottethomas clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT singhnaveena clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT sahdevanju clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT funinganaionutgabriel clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT jimenezlinanmercedes clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT markowetzflorian clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT brentonjamesd clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT salaevis clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma
AT woitekramona clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma